Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
Anti-aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "Anti-aggregation" in MCE Product Catalog:
4
Category:
Triterpenes Neurological Disease Terpenoids Leguminosae Extract Plants Disease Research Fields Glycyrrhiza uralensis Fisch. Inflammation/Immunology
Target:
1
1 Cited Publications
Target:
Research Areas:
Fentiazac, alkanoic acid derivative, is an orally active non-steroidal anti-inflammatory agent, with analgesic, antipyretic and platelet anti-aggregation activity. Fentiazac can be used to research inflammatory diseases such as rheumatoid arthritis, osteoarthritis and tendinitis .
Cat. No.: HY-175552
Target:
Research Areas:
Cat. No.: HY-N12360
CAS No.: 25166-14-7
Target:
Target:
Cat. No.: HY-17482
CAS No.: 51484-40-3
Synonyms: Z-876
Target:
Research Areas:
Difenpiramide (Z-876) is a bisphenylalcanoic derivative with marked anti-inflammatory, analgesic, antipyretic and uricosuric properties. Difenpiramide has platelet anti-aggregation activity .
Cat. No.: HY-19255
CAS No.: 227951-89-5
Target:
Research Areas:
FK-788 is a PGI(2) and IP agonist with a strong anti-aggregation effect, with an IC50 of 18 nM and a high binding affinity for the human recombinant IP receptor, with a Ki value of 20 nM .
Cat. No.: HY-N12360R
CAS No.: 25166-14-7
Target:
Target:
Cat. No.: HY-118752R
CAS No.: 18046-21-4
Target:
Research Areas:
Fentiazac (Standard) is the analytical standard of Fentiazac. This product is intended for research and analytical applications. Fentiazac, alkanoic acid derivative, is an orally active non-steroidal anti-inflammatory agent, with analgesic, antipyretic and platelet anti-aggregation activity. Fentiazac can be used to research inflammatory diseases such as rheumatoid arthritis, osteoarthritis and tendinitis .
Target:
Research Areas:
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC50 of 0.18 μM. MAO-B-IN-9 prevents Aβ1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-182304
CAS No.: 1338489-62-5
Research Areas:
CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) .
Cat. No.: HY-180346
CAS No.: 64134-31-2
Target:
Research Areas:
Cat. No.: HY-184817
CAS No.: 2883627-63-0
Research Areas:
α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease .
Cat. No.: HY-184815
CAS No.: 2883627-67-4
Research Areas:
α-Synuclein-IN-20 is an inhibitor of α-synuclein (α-Synuclein) with an IC50 of 4.1 μM against human α-Syn. α-Synuclein-IN-20 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-20 scavenges ROS, protects and repairs dopaminergic neurons, ameliorates Parkinson's disease-like symptoms, and shows low cytotoxicity. α-Synuclein-IN-20 can be used for research related to Parkinson's disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
